The CASP9 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian cancer cell line, featuring targeted disruption of the CASP9 gene that encodes the initiator caspase-9. This heterogeneous knockout pool provides a robust loss-of-function model for studying intrinsic apoptosis in ovarian cancer biology, without selection of a single clone, thereby preserving biological variability.
The A2780 cell line was originally isolated from an untreated ovarian endometrioid adenocarcinoma and has since become a widely adopted model in ovarian cancer research. These adherent epithelial cells retain characteristic oncogenic features, including relevant mutations and signaling pathway alterations, making them a valuable substrate for investigating tumor progression, metastasis, and therapeutic response mechanisms.
CASP9 functions as the apical initiator caspase of the intrinsic apoptosis pathway. In response to apoptotic stimuli, mitochondrial outer membrane permeabilization releases cytochrome c (CYCS), which binds to the adaptor protein APAF1, facilitating the assembly of the apoptosome complex. Within this heptameric platform, pro-CASP9 undergoes autocatalytic cleavage and activation. Active CASP9 then proteolytically processes the executioner caspases-3 (CASP3), -6 (CASP6), and -7 (CASP7), which in turn cleave numerous substrates, including the DNA repair enzyme PARP1, to execute the orderly dismantling of the cell. Upstream regulation is governed by the BCL2 protein family: pro-apoptotic members BAX, BAK, BAD, and BID promote mitochondrial permeabilization, while anti-apoptotic BCL2 and BCL-XL preserve mitochondrial integrity. The tumor suppressor p53 transcriptionally induces several pro-apoptotic BCL2 family genes, directly linking genotoxic stress to apoptosis. Negative regulators such as XIAP and BIRC5/Survivin bind and inhibit active caspases, a constraint relieved by the mitochondrial release of SMAC/DIABLO. Additionally, the chaperone HSP70 can interact with CASP9 and modulate apoptosome formation, adding another layer of control.
Knocking out CASP9 in the A2780 ovarian cancer cell background allows precise dissection of intrinsic apoptosis pathways in a disease-relevant context. Ovarian carcinomas often exhibit dysregulated apoptosis, contributing to chemoresistance and tumor survival. This model enables investigation of how loss of the initiator caspase reshapes cell fate decisions following DNA damage, targeted therapy, or mitochondrial stress, offering insights into p53-dependent and BCL2 family-mediated apoptotic thresholds. It is especially useful for validating the role of CASP9 in drug-induced cell death and for identifying bypass mechanisms that allow cancer cells to evade apoptosis.
These polyclonal CASP9 knockout cells are ideal for a broad range of apoptosis-related experiments, including mechanistic studies of apoptosis signaling, screening of pro-apoptotic compounds, and analysis of mitochondrial dysfunction. Researchers can confirm target protein ablation by Western blotting for cleaved CASP9 or by fluorometric caspase-9 activity assays. Functional cell death assays such as cytochrome c release measurements, TUNEL staining, and Annexin V/propidium iodide flow cytometry provide quantitative endpoints. Co-immunoprecipitation with APAF1 can verify defective apoptosome formation. Applications also extend to combinatorial drug testing, CRISPR rescue experiments, and functional genomics screens aimed at uncovering pro-survival pathways in ovarian cancer. For additional technical details or ordering inquiries, please contact Ascent Research.
